The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.

2025-521400-21-00 Protocol 1028/25 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 15 May 2025 · End 25 Sep 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1028/25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 54
Countries 1
Sites 1

Not applicable (submitted trial is a BE study in healthy subjects).

Key facts

Sponsor
Adamed Pharma S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Mental Disorders [F03]
Trial duration
15 May 2025 → 25 Sep 2025
Decision date (initial)
2025-05-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Not applicable (submitted trial is a BE study in healthy subjects).

VersionLevelCodeTermSystem organ class
20.0 PT 10039626 Schizophrenia 100000004873

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Adamed Pharma S.A.

Sponsor organisation
Adamed Pharma S.A.
Address
Ul. Mariana Adamkiewicza 6a, Pienkow Pienkow
City
Czosnow
Postcode
05-152
Country
Poland

Scientific contact point

Organisation
Adamed Pharma S.A.
Contact name
Pharmacokinetic Study Team

Public contact point

Organisation
Adamed Pharma S.A.
Contact name
Pharmacokinetic Study Team

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 54 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinic, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-05-15 2025-09-25 2025-05-26 2025-06-07

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-11 Czechia Acceptable
2025-05-14
2025-05-14
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-01 Czechia Acceptable
2025-05-14
2025-12-01